Rimegepant in Real-World Migraine Prevention

from TheBrief.Health · host TheBrief.Health

A real-world study shows rimegepant effectively prevents migraines in treatment-resistant patients, including some after CGRP antibody failure, supporting earlier use for improved long-term outcomes.

Episode metadata supplied by the publisher feed · Published Aug 4, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

Rimegepant in Real-World Migraine Prevention

0:00 1:50

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of TheBrief.Health?

This episode is 1 minute long.

When was this TheBrief.Health episode published?

This episode was published on August 4, 2026.

Can I download this TheBrief.Health episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!